echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Urinary System > 42% lower risk of death! The team of Ye Dingwei of Fudan University released the first Chinese plan for the treatment of metastatic hormone-sensitive prostate cancer

    42% lower risk of death! The team of Ye Dingwei of Fudan University released the first Chinese plan for the treatment of metastatic hormone-sensitive prostate cancer

    • Last Update: 2022-09-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit

    On September 5, 2022, the team of Ye Dingwei of the Department of Urology of the Affiliated Cancer Hospital of Fudan University published a research paper in the journal Lancet Oncology, which lasted more than 4 years, comparing the efficacy and safety of "revirutrum combined castration therapy" and the classic "bicalutamide combined castration therapy" in patients with high tumor load metastatic hormone-sensitive prostate cancer, confirming the first new second-generation anti-male drug "revirutamine" independently developed by China.

    This article is the original of translational medicine network, please indicate the source when reprinting

    Author: Jevin

    The dilemma of prostate cancer treatment needs to be solved urgently


    Prostate cancer is a malignant tumor with a very high incidence, ranking second in the world in the incidence of malignant tumors in men, after lung cancer

    The treatment effect of early prostate cancer is good, and recently the Affiliated Cancer Hospital of Fudan University released 6,000 cases of early prostate cancer efficacy data, Professor Ye Dingwei said: "The 5-year survival rate of early patients is nearly 100%.

    Significant effect of the "Chinese Protocol" for the treatment of prostate cancer


    At present, the general prostate cancer treatment options are mostly based on research in developed countries in

    Professor Ye Dingwei's delegation targeted the drug "Reverrumide", a new androgen receptor inhibitor with independent intellectual property rights in China, which has made important innovations and improvements in molecular structure and is more suitable for Chinese prostate cancer populations

    The results of the study showed that compared with the bicalutamide group, the risk of imaging progression or death in the revruminate group was reduced by 56%, and the survival time of the patients was significantly longer, and the risk of death was reduced by 42%; Patients in the revirutamide group also showed significant benefits at secondary and exploratory efficacy endpoints; In addition, the Riviruamine group also showed excellent safety.

    Professor Ye Dingwei said: "Compared with the classic protocol, patients have a longer survival time and higher drug safety, which means that there is a new Chinese solution for

    Innovative drug development will bring new hope to more terminal patients


    "In the public perception, there is often a misunderstanding of drug clinical research, worried about becoming a guinea pig in new drug research," Professor Ye Dingwei said, "In fact, drug clinical research often brings more choices to patients, so that advanced patients who have lost treatment opportunities can use international cutting-edge drugs, which will also greatly reduce the economic burden on some patients, and will also get more comprehensive attention during medication, and the success of CHART research is a good example

    Professor Ye Dingwei has led more than 70 international and domestic multi-center clinical research on new drugs and new technologies for urinary tumors, accounting for 80%

    Early detection and early treatment are still the key prerequisites


    This article is intended to introduce the progress of medical research and cannot be used as a reference for

    Testimonials/ Live Events

    September 27, 14:00-17:30 Shanghai

    Innovative technology to help tumor accurate diagnosis and treatment summit forum

    Scan the code to participate for free

    November 03-04 09:00-17:30 Shanghai

    The 3rd Yangtze River Delta In Vitro Diagnostic Industry Forum

    Scan the code to participate for free

    November 25-27 09:00-17:30 Shanghai

    The 4th Shanghai International Conference on Cancer

    Scan the code to participate

    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.